X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
CORT125134 (relacorilant) is a selective cortisol modulator that binds to the glucocorticoid receptor, but does not bind to the body's other hormone receptors. It is being evaluated for the treatment of cushing’s syndrome.
Lead Product(s): Relacorilant
Therapeutic Area: Endocrinology Product Name: CORT125134
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2024
Details:
CORT125134 (relacorilant) is a selective cortisol modulator that binds to the glucocorticoid receptor. It is being evaluated in combination with nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer.
Lead Product(s): Relacorilant,Paclitaxel
Therapeutic Area: Oncology Product Name: CORT125134
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2024
Details:
CORT125134 (relacorilant) is a selective cortisol modulator that binds to the glucocorticoid receptor. It is being evaluated for the treatment of adrenal cushing’s syndrome.
Lead Product(s): Relacorilant
Therapeutic Area: Endocrinology Product Name: CORT125134
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
Phase 2 trial showed that CORT-125134 (relacorilant) plus nab-paclitaxel improved progression-free survival, duration of response and overall survival without an increased side effect burden compared to nab-paclitaxel alone.
Lead Product(s): Relacorilant,Paclitaxel
Therapeutic Area: Oncology Product Name: CORT-125134
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
Details:
In Corcept’s Phase 2 trial, women who met the entry criteria for ROSELLA and received CORT-125134 (relacorilant) exhibited substantial benefit, without increasing the frequency or severity of adverse events.
Lead Product(s): Relacorilant,Paclitaxel
Therapeutic Area: Oncology Product Name: CORT-125134
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Relacorilant is a non-steroidal, selective modulator of glucocorticoid receptor. Results show statistically significant and clinically benefit experienced by women with recurrent platinum-resistant ovarian cancer who were treated with nab-paclitaxel plus Relacorilant.
Lead Product(s): Relacorilant,Paclitaxel
Therapeutic Area: Oncology Product Name: CORT-125134
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2021
Details:
RELIANT is a single-arm, multicenter, open-label, Phase 3 trial of relacorilant combined with nab-paclitaxel in patients with metastatic pancreatic cancer, with a planned enrollment of 80 patients and a planned interim analysis of outcomes in the first 40 patients.
Lead Product(s): Relacorilant,Paclitaxel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2021
Details:
GRADIENT is a double-blind, placebo-controlled Phase 3 trial, with a planned enrollment of 130 patients at sites in the United States and Europe. Half of the patients will receive relacorilant and the other half placebo for six months.
Lead Product(s): Relacorilant
Therapeutic Area: Endocrinology Product Name: CORT125134
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2020
Details:
Corcept completed enrollment in its controlled, Phase 2 trial of relacorilant combined with nab-paclitaxel (Abraxane®) in patients with metastatic, platinum-resistant ovarian cancer.
Lead Product(s): Relacorilant,Paclitaxel
Therapeutic Area: Oncology Product Name: CORT125134
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 23, 2020
Details:
Company enrolled first patient in RELIANT, an open-label, Phase 3 trial of relacorilant in combination with nab-paclitaxel (Celgene’s medication, Abraxane®) in patients with metastatic pancreatic cancer.
Lead Product(s): Relacorilant,Enzalutamide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
